Reinterpreting cardiorenal protection of renal sodium–glucose cotransporter 2 inhibitors via cellular life history programming

Diabetes Care

Volumn 43, Issue 3, 2020, Pages 501-507

  Avogaro, Angelo ^a   Fadini, Gian Paolo ^a   Del Prato, Stefano ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; HORMONE; KETONE; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; GLUCOSE; SODIUM;

ADIPOSE TISSUE; ARTICLE; CELL ACTIVITY; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; GENE EXPRESSION; GLUCONEOGENESIS; GLYCOLYSIS; HEART PROTECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLAMMATION; LIPID OXIDATION; MACROPHAGE; METABOLIC RATE; MICROENVIRONMENT; NONHUMAN; OBESITY; POLARIZATION; RENAL PROTECTION; STRESS; ANIMAL; DIET RESTRICTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR REPROGRAMMING;

ANIMALS; CELLULAR REPROGRAMMING; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE; HUMANS; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85081100096     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc19-1410     Document Type: Article

References (97)

1. Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 2017;26:27–38
2. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017;13: 11–26
3. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016;374: 1094
4. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657
5. Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357
6. Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306
7. Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia 2017;60:395–398
8. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016;39: 1115–1122
9. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2018; 41:356–363
10. 1 exchanger in rats and rabbits. Diabetologia 2017;60:568–573
11. Wang A, Luan HH, Medzhitov R. An evolutionary perspective on immunometabolism. Science 2019;363:363
12. Lee YS, Wollam J, Olefsky JM. An integrated view of immunometabolism. Cell 2018;172:22–40
13. Kajantie E, Osmond C, Barker DJ, Forsén T, Phillips DI, Eriksson JG. Size at birth as a predictor of mortality in adulthood: a follow-up of 350 000 person-years. Int J Epidemiol 2005;34:655–663
14. Kajantie E, Feldt K, Räikkönen K, et al. Body size at birth predicts hypothalamic-pituitaryadrenal axis response to psychosocial stress at age 60 to 70 years. J Clin Endocrinol Metab 2007; 92:4094–4100
15. Phillips DI, Barker DJ, Fall CH, et al. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J Clin Endocrinol Metab 1998;83: 757–760
16. Song H, Fang F, Arnberg FK, et al. Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. BMJ 2019;365:l1255
17. Heidt T, Sager HB, Courties G, et al. Chronic variable stress activates hematopoietic stem cells. Nat Med 2014;20:754–758
18. Hilliard ME, Yi-Frazier JP, Hessler D, Butler AM, Anderson BJ, Jaser S. Stress and A1c among people with diabetes across the lifespan. Curr Diab Rep 2016;16:67
19. Livingstone SJ, Levin D, Looker HC, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313:37–44
20. Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol 2015;3:114–122
21. Wiebe JC, Santana A, Medina-Rodríguez N, et al.; T1DGC. Fertility is reduced in women and in men with type1 diabetes: Results from the Type1 Diabetes Genetics Consortium (T1DGC). Diabetologia 2014;57:2501–2504
22. Kültz D. Molecular and evolutionary basis of the cellular stress response. Annu Rev Physiol 2005;67:225–257
23. Lorenzo C, Hanley AJ, Haffner SM. Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 2014;57:83–92
24. Fadini GP, Marcuzzo G, Marescotti MC, de Kreutzenberg SV, Avogaro A. Elevated white blood cell count is associated with prevalence and development of the metabolic syndrome and its components in the general population. Acta Diabetol 2012;49:445–451
25. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 2002;40:1761–1768
26. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045–2051
27. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–1131
28. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207
29. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature 2012;487:325–329
30. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 2007; 18:1437–1446
31. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 2005;5:844–852
32. Tawakol A, Singh P, Mojena M, et al. HIF-1a and PFKFB3 mediate a tight relationship between proinflammatory activation and anerobic metabolism in atherosclerotic macrophages. Arterioscler Thromb Vasc Biol 2015;35:1463–1471
33. Bories GFP, Leitinger N. Macrophage metabolism in atherosclerosis. FEBS Lett 2017;591: 3042–3060
34. Campbell MA. Dormancy and the cell cycle. Genet Eng (N Y) 2006;27:21–33
35. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998;339:173–181
36. Kung CP, Murphy ME. The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 2016;231:R61–R75
37. White E. Autophagy and p53. Cold Spring Harb Perspect Med 2016;6:a026120
38. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573–25580
39. Kokkinos J, Tang S, Rye KA, Ong KL. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis 2017;257:259–265
40. Xie T, Leung PS. Fibroblast growth factor 21: A regulator of metabolic disease and health span.Am J Physiol Endocrinol Metab 2017;313:E292–E302
41. Staiger H, Keuper M, Berti L, Hrabe de Angelis M, Häring HU. Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev 2017;38:468–488
42. Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018;61: 1923–1934
43. Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 2017;20:137–149
44. Osataphan S, Macchi C, Singhal G, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight 2019;4:4
45. Kosugi R, Nakatani E, Okamoto K, Aoshima S, Arai H, Inoue T. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients. Endocr J 2019;66:677–682
46. Krilowicz BL. Ketone body metabolism in a ground squirrel during hibernation and fasting. Am J Physiol 1985;249:R462–R470
47. Apostolopoulou M, Strassburger K, Herder C, et al.; GDS group. Metabolic flexibility and oxidative capacity independently associate with insulin sensitivity in individuals with newly diagnosed type 2 diabetes. Diabetologia 2016;59: 2203–2207
48. Esterline RL, Vaag A, Oscarsson J, Vora J. MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? Eur J Endocrinol 2018;178: R113–R125
49. Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol 2019;20:436–450
50. Jones RG, Pearce EJ. MenTORing immunity: mTOR signaling in the development and function of tissue-resident immune cells. Immunity 2017; 46:730–742
51. Snyder JP, Amiel E. Regulation of dendritic cell immune function and metabolism by cellular nutrient sensor mammalian target of rapamycin (mTOR). Front Immunol 2019;9:3145
52. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B. The role of PPARs in atherosclerosis. Trends Mol Med 2002;8:422–430
53. Inoue MK, Matsunaga Y, Nakatsu Y, et al. Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice. Diabetol Metab Syndr 2019;11:57
54. Sayour AA, Korkmaz-Icöz S, Loganathan S, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 2019;17:127
55. Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol 2015;15:599–614
56. Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol 2019;317:F767–F780
57. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013;715: 246–255
58. -/- mice fed a western diet. Diabetologia 2017;60:364–376
59. Birnbaum Y, Bajaj M, Yang HC, Ye Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther 2018;32:135–145
60. Scheen AJ, Esser N, Paquot N. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes Metab 2015;41: 183–194
61. Prattichizzo F, De Nigris V, Micheloni S, La Sala L, Ceriello A. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? Diabetes Obes Metab 2018;20:2515–2522
62. Wang D, Luo Y, Wang X, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice. Int J Mol Sci 2018;19:137
63. Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 2019;62: 1154–1166
64. Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 2017;16:138
65. Lee DM, Battson ML, Jarrell DK, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut micro-biota in type 2 diabetic mice. Cardiovasc Diabetol 2018;17:62
66. Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DE-FENCE study. Cardiovasc Diabetol 2017;16:84
67. Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 2018;15:335–346
68. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018;44:457–464
69. Miyachi Y, Tsuchiya K, Shiba K, et al. A reduced M1-like/M2-like ratio of macrophages in healthy a dipose tissue expansion during SGLT2 inhibition. Sci Rep 2018;8:16113
70. Bouma HR, Strijkstra AM, Boerema AS, et al. Blood cell dynamics during hibernation in the European Ground Squirrel. Vet Immunol Immunopathol 2010;136:319–323
71. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849–2852
72. Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 2016;101:3506–3515
73. McPherson PA, McEneny J. The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress. J Physiol Biochem 2012;68:141–151
74. Sawada Y, Izumida Y, Takeuchi Y, et al. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. Biochem Bio-phys Res Commun 2017;493:40–45
75. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004;70:309–319
76. Williams CT, Barnes BM, Buck CL. Integrating physiology, behavior, and energetics: biologging in a free-living arctic hibernator. Comp Biochem Physiol A Mol Integr Physiol 2016;202:53–62
77. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015;21:263–269
78. Gambhir D, Ananth S, Veeranan-Karmegam R, et al. GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:2208–2217
79. Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology 2016;157:1029–1042
80. Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000;275:12633–12638
81. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993–1007
82. Dumortier M, Brandou F, Perez-Martin A, Fedou C, Mercier J, Brun JF. Low intensity endurance exercise targeted for lipid oxidation improves body composition and insulin sensitivity in patients with the metabolic syndrome. Diabetes Metab 2003;29:509–518
83. Trenell MI, Hollingsworth KG, Lim EL, Taylor R. Increased daily walking improves lipid oxidation without changes in mitochondrial function in type 2 diabetes. Diabetes Care 2008;31:1644–1649
84. Toth MJ, Tchernof A. Lipid metabolism in the elderly. Eur J Clin Nutr 2000;54(Suppl. 3):S121–S125
85. Huang SC, Everts B, Ivanova Y, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol 2014;15:846–855
86. Malandrino MI, Fucho R, Weber M, et al. Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. Am J Physiol Endocrinol Metab 2015;308:E756–E769
87. Bauman WA, Meryn S, Florant GL. Pancreatic hormones in the nonhibernating and hibernating golden mantled ground squirrel. Comp Biochem Physiol A Comp Physiol 1987;86:241–244
88. Bauman WA. Seasonal changes in pancreatic insulin and glucagon in the little brown bat (Myotis lucifugus). Pancreas 1990;5:342–346
89. Naznin F, Sakoda H, Okada T, et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus and skeletal muscle of mice. Eur J Pharmacol 2017;794:37–44
90. Ross R, Wang PY, Chari M, et al. Hypothalamic protein kinase C regulates glucose production. Diabetes 2008;57:2061–2065
91. Forreider B, Pozivilko D, Kawaji Q, Geng X, Ding Y. Hibernation-like neuroprotection in stroke by attenuating brain metabolic dysfunction. Prog Neurobiol 2017;157:174–187
92. Zancanaro C, Malatesta M, Mannello F, Vogel P, Fakan S. The kidney during hibernation and arousal from hibernation. A natural model of organ preservation during cold ischaemia and reperfusion. Nephrol Dial Transplant 1999;14: 1982–1990
93. Suh HN, Lee YJ, Kim MO, Ryu JM, Han HJ. Glucosamine-induced Sp1 O-GlcNAcylation ameliorates hypoxia-induced SGLT dysfunction in primary cultured renal proximal tubule cells. J Cell Physiol 2014;229:1557–1568
94. Widya RL, Hammer S, Boon MR, et al. Effects of short-term nutritional interventions on right ventricular function in healthy men. PLoS One 2013;8:e76406
95. Hagen I, Schulte DM, Müller N, et al. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine 2015;73:265–269
96. Jordan S, Tung N, Casanova-Acebes M, et al. Dietary intake regulates the circulating inflammatory monocyte pool. Cell 2019;178:1102–1114.e17
97. Lyons CL, Roche HM. Nutritional modulation of AMPK-impact upon metabolic-inflammation. Int J Mol Sci 2018;19:3092